Metalabs Reports Q3 Sales of 30 Billion Won, Up 237% Year-on-Year

Metalabs announced in its third-quarter earnings report that sales reached 30 billion won, a 237% increase compared to the same period last year. Cumulative sales amounted to 50.2 billion won, up 78% year-on-year, while operating losses stood at 250 million won.

A company representative explained, "Sales from the newly launched business division in June have begun to grow in earnest, and the consolidation of subsidiaries such as Metacare has also contributed to the increase in revenue."

Metalabs plans to focus on strengthening new business initiatives and improving subsidiary management efficiency in the fourth quarter, aiming to reduce operating losses and pursue stable growth.

In particular, since the second half of this year, the company has been developing premium luxury brand licensing and vendor businesses targeting major home shopping and live commerce channels. Through these efforts, Metalabs intends to accelerate business stabilization and reinforce its profit structure going forward.

Its subsidiary MetaSNC is also working to improve performance by expanding sales of its CRM (Customer Relationship Management) solutions. Furthermore, the company plans to continuously expand into the digital healthcare sector leveraging its IT capabilities, including solution-based medical big data businesses, to proactively respond to the upcoming artificial intelligence (AI) era and secure long-term growth drivers.

A Metalabs representative stated, "We are creating new market opportunities based on the expertise and capabilities we have accumulated in the fashion business," adding, "We aim for significant growth in 2026 by continuously expanding our business not only in fashion but also in the medical sector."

Meanwhile, Metacare, a KOSPI-listed subsidiary of Metalabs, posted third-quarter sales of 16.7 billion won and operating profit of 2.05 billion won, marking increases of 14.7% and 195% respectively compared to the same period last year. This was attributed to a significant rise in the number of surgeries at key client medical institutions in its prescription drug, medical device, and medical consumables supply business.

In addition, Metacare is expanding its supply network from general and semi-general hospitals to pharmacies nationwide, and plans to newly enter the medical device supply business based on a recently acquired hair loss medical consulting company.

This content was produced with the assistance of AI translation services.